Creative Planning Has $11.43 Million Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Creative Planning cut its holdings in Becton, Dickinson and Company (NYSE:BDX) by 0.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 47,387 shares of the medical instruments supplier’s stock after selling 318 shares during the quarter. Creative Planning’s holdings in Becton, Dickinson and Company were worth $11,425,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Ameriprise Financial Inc. raised its position in shares of Becton, Dickinson and Company by 6.4% in the second quarter. Ameriprise Financial Inc. now owns 5,055,354 shares of the medical instruments supplier’s stock valued at $1,181,483,000 after purchasing an additional 302,893 shares during the period. Massachusetts Financial Services Co. MA increased its position in Becton, Dickinson and Company by 1.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 4,905,114 shares of the medical instruments supplier’s stock worth $1,146,374,000 after acquiring an additional 87,230 shares during the period. Bank of New York Mellon Corp increased its position in Becton, Dickinson and Company by 8.5% during the second quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock worth $1,031,167,000 after acquiring an additional 346,720 shares during the period. Clearbridge Investments LLC increased its position in Becton, Dickinson and Company by 3.1% during the second quarter. Clearbridge Investments LLC now owns 2,984,524 shares of the medical instruments supplier’s stock worth $697,513,000 after acquiring an additional 89,157 shares during the period. Finally, First Eagle Investment Management LLC increased its position in Becton, Dickinson and Company by 32.5% during the second quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock worth $655,149,000 after acquiring an additional 688,296 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently issued reports on BDX shares. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Evercore ISI boosted their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Stifel Nicolaus boosted their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Finally, Raymond James lowered their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Stock Down 0.4 %

Shares of NYSE:BDX opened at $239.66 on Wednesday. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $262.23. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. The company’s fifty day moving average is $237.20 and its 200-day moving average is $235.12. The company has a market capitalization of $69.26 billion, a PE ratio of 52.79, a P/E/G ratio of 1.79 and a beta of 0.42.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.31 by $0.19. The business had revenue of $4.99 billion for the quarter, compared to the consensus estimate of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.96 EPS. Equities research analysts predict that Becton, Dickinson and Company will post 13.11 earnings per share for the current fiscal year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.